Roche's Phesgo to treat HER2─positive breast cancer gets US FDA approval

Roche announced that the US Food and Drug Administration (US FDA) has approved Phesgo, a fixed─dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy